

**What is New in Heparin Use?**

**October 19, 2018**

**15:20-16:40, Conference Hall No.2-A (2F)**

**Moderators: Debra A. Hoppensteadt, Shaker Mousa , Yiming Yao**

**15:20-15:32 Diversification of Heparins! What are the Challenges?**

**Debra A. Hoppensteadt (United States)**

**15:32-15:44 Heparin Related Glycosaminoglycans: Clinical Use and Future Developments**

**Shaker Mousa (United States)**

**15:44-15:56 Rationale for the Therapeutic Effects of Sulodexide and Danaparoid**

**Jawed Fareed, Jeanine Walenga (United States)**

**15:56-16:08 Heparins and recanalization**

**Pavel Poredos (Slovenia)**

**16:08-16:20 Heparins and Related Drugs in the Era of New Anticoagulants**

**Jawed Fareed (United States)**

**16:20-16:40 Discussion**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Despite several advances in the development of anticoagulant drugs, unfractionated heparin remain to be the only parenteral anticoagulant for surgical, interventional and medical usage. Low molecular weight heparins and Fondaparinux have added a new dimension to the management of thrombosis. Heparinoids such as Sulodexide and Danaparoid are also used for various indications. Unfractionated heparins resourced from bovine and porcine tissues have become available to meet the supply and demand. Generic versions of low molecular weight heparins and pentasaccharide are also available. This symposium is organized to discuss the current developments in the introduction of these agents for vascular indications. This symposium is organized under the auspices of Loyola University Chicago, North American Thrombosis Forum and the North American Chapter of the IUA.**